uniQure 3Q 2026: Revenue $5.2M, Net income ($61.22M), EPS ($0.88) — 10-Q Summary

What happened

uniQure reported third-quarter 2026 revenue of $5.2 million, up 40.4% from a year earlier. Its net loss narrowed to $61.22 million from $80.53 million, and diluted loss per share improved to $0.88 from $1.38. The FDA granted Priority Review to its Huntington’s disease application, with a May 1, 2027 target date.

Confirmed

Global impact / market context

Higher revenue alongside a smaller net loss points to improved reported results, but the company still lost $61.22 million in the quarter. The FDA review timetable could shape expectations for the Huntington’s disease program; approval could open a route to product revenue, while trial and development costs remain relevant.

Analyst inference

The update combines financial results with clinical and regulatory milestones. HEMGENIX royalty revenue reached $14.6 million for the first nine months, up from $10.4 million a year earlier, while Huntington’s disease data were mixed at 48 months. These details frame both existing revenue and development uncertainty.

Confirmed

What to watch

1. Watch for the FDA’s decision by the stated May 1, 2027 target date; the outcome would determine whether the Huntington’s disease program advances toward potential U.S. sales. Analyst inference
2. Track whether uniQure begins screening by year-end 2026 for its planned confirmatory trial of about 200 patients, since enrollment progress will affect development timing and costs. Proposed
3. Follow upcoming clinical updates, including longer-term Huntington’s results and progress in the AMT-260 and AMT-191 studies, for evidence that could strengthen or weaken development prospects. Analyst inference

Evidence

• Original source link unavailable